Research programme: nerve growth factor therapeutics - ChiesiAlternative Names: hNGF P61S; hNGF P61SR100E; hNGF R100E; NGF P61SR100E
Latest Information Update: 15 Jun 2016
At a glance
- Originator Chiesi
- Class Nerve growth factors
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Jun 2016 Preclinical trials in Undefined indication in Italy (unspecified route)
- 15 Sep 2015 Early research in Undefined indication in Italy (unspecified route)